Related Experiment Videos
A differentiation switch for genetically modified hepatocytes
Carla Boccaccio1, Margherita Ando', Paolo M Comoglio
1Institute for Cancer Research and Treatment, University of Torino Medical School, 10060 Candiolo-Torino, Italy. cboccaccio@ircc.unito.it
Summary
Scientists engineered a hepatocyte growth factor receptor (HGFR) molecule that selectively triggers cell differentiation, not proliferation. This controlled differentiation of hepatocytes offers new therapeutic potential without unwanted cell expansion.
Area of Science:
- Cell biology
- Molecular signaling
- Regenerative medicine
Background:
- Hepatocyte growth factor receptor (HGFR) signaling controls cell proliferation and differentiation.
- Branching morphogenesis, a key HGFR-mediated process, involves cell scatter, tubule formation, and apoptosis resistance.
Purpose of the Study:
- To investigate if the differentiative functions of HGFR can be selectively activated.
- To develop a tool for controlling hepatocyte differentiation without inducing proliferation.
Main Methods:
- Fusion of the intracellular HGFR domain with FK506-binding protein (FKBP) domains and a membrane-targeting signal to create FKBP-HGFR.
- Induction of FKBP-HGFR dimerization using a bifunctional ligand.
- Analysis of downstream signaling kinetics, including tyrosine kinase and MAP kinase activation.
Main Results:
- FKBP-HGFR dimerization in mouse hepatocyte progenitors induced cell scatter, morphogenesis, and apoptosis protection, mimicking the differentiative HGFR response.
- FKBP-HGFR did not induce cell proliferation.
- Distinct signaling kinetics were observed: reduced/prolonged tyrosine kinase activation and a low, sustained MAP kinase activation peak.
Conclusions:
- The biological response of HGFR can be segregated based on quantitative signaling profiles.
- FKBP-HGFR allows selective control of hepatocyte differentiation, uncoupled from proliferation.
- This engineered receptor offers potential for targeted regenerative medicine applications.